

Manhattan Scientifics Exclusive Distribution To Mass Populations In Russia

October 15, 2010

"We're living longer and we need new parts. We're very excited about this agreement, especially considering the tremendous potential of the medical prosthetics market. The bottom line is that dental implants are just the tip of the iceberg of what is estimated to be a \$20 billion annual market."

ALBUQUERQUE, N.M.--Manhattan Scientifics, Inc. (OTC: MHTX) announced that at today's historic press conference introducing the use of the first FDA-approved dental implant made with nanotitanium, the company will sign a letter of intent with NanoMet, the Russian enterprise that helped create nanotitanium (titanium on steroids) to participate in the distribution of dental implants in Russia. The dental implants will be manufactured by Basic Dental Inc., the Albuquerque-based manufacturer of America's first nanotitanium dental implants, which possess the ability to bond more quickly to human bone and promote faster healing.

Manhattan Scientifics Founder Marvin Maslow said, "We're living longer and we need new parts. We're very excited about this agreement, especially considering the tremendous potential of the medical prosthetics market. The bottom line is that dental implants are just the tip of the iceberg of what is estimated to be a \$20 billion annual market."

For more information and detail, please read today's Forbes.com story titled, Using Cold War Tech for Peacetime Healing (<http://www.forbes.com/2010/10/14/weapons-healthcare-implants-technology-nanotitanium.html>).

The dental implant is manufactured and distributed by Basic Dental Inc. of Albuquerque, under a limited license from Manhattan Scientifics, who also issued a broader exclusive license to a major Fortune /1000 U.S. NYSE metals manufacturing company to cover other medical and non-medical applications for the new class of super strong / super light metals.

About Manhattan Scientifics

Manhattan Scientifics, Inc., (OTCBB: MHTX), is a leading information age enterprise focused on the nanomedicine space. Located in New Mexico, New York and Montreal, Manhattan Scientifics' goal is to create profit for the company's shareholders through royalty-bearing licenses with Fortune 1000 companies by marketing products that rely on the company's patents, know-how and intellectual property. Manhattan Scientifics owns the exclusive, perpetual U.S. license to a family of patents which will enable the manufacture and marketing of super strong, ultra light-weight "nanostructured" metals that have been developed at the Los Alamos National Laboratory (LANL) and in the former Soviet Union. More information about Manhattan Scientifics can be found at www.mhtx.com and at www.seniorscientific.com

Forward-looking statement

This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.



Contacts

Manhattan Scientifics, Inc.

Marvin Maslow, Director of PR & IR, 917-923-3300

Email: marvin@mhtx.com

U.S. & Canadian Investor Relations

Hawk Associates: Frank Hawkins, 305-451-1888

Email: f.hawkins@hawkassociates.com